GNRH1 and prostate cancer: Similarly, Smith et al. studied 40 patients with prostate cancer for 48 weeks and found that GnRH agonist treatment increased serum concentrations of TC, HDL cholesterol, LDL cholesterol, and TG by 9.0 ± 2.1%, 11.3 ± 2.6%, 7.3 ± 3.5%, and 26.5 ± 10.0%, respectively, in their participants [20].